Have you ever wondered how longevity medicine is moving beyond broad “anti-aging” concepts toward treatments aimed directly at the biology of aging? One area receiving increasing attention is senolytic therapy, which focuses on clearing aged, inflammation-producing senescent cells that accumulate over time.
Senolytics and cellular-longevity protocols are being investigated as a way to address senescent-cell burden through carefully selected compounds, intermittent treatment schedules, clinical screening, and ongoing monitoring. Current approaches may incorporate fisetin, quercetin, dasatinib, rapamycin, spermidine, and NAD+ as part of a broader, medically supervised longevity strategy.
Purpose & Ground Rules
Longevity medicine is shifting from vague “anti-aging” toward precision treatments aimed at the biology of aging itself. The leading edge right now is senolytics – clearing aged, inflammation-producing “senescent” cells.
The goal is to deliver measurably better patient outcomes through carefully structured longevity care, appropriate patient selection, quality-controlled components, individualized dosing, and rigorous monitoring.
This is investigational medicine. No senolytic is FDA-approved to treat aging, frailty, or extend lifespan. Every use is off-label and experimental, and patients should understand this distinction clearly before beginning treatment.
Clinical decisions regarding patient selection, prescribing, dosing, and monitoring belong to credentialed healthcare providers.
Treatment should not move forward without appropriate medical review, informed consent, and confirmation that any compounded components comply with applicable pharmacy and regulatory requirements.
The Science of Senolytics
When a cell is damaged or stressed, it can stop dividing yet refuse to die. These senescent cells remain in the body and secrete inflammatory signals known as the senescence-associated secretory phenotype (SASP).
A certain number of senescent cells are normal and can serve useful functions, including wound healing and tumor suppression. The problem occurs when these cells accumulate with age.
This accumulation contributes to chronic low-grade inflammation, sometimes referred to as “inflammaging,” and can push nearby healthy cells toward dysfunction. Research has linked senescent-cell burden with frailty, osteoarthritis, fibrosis, and metabolic decline.
Senolytics are designed to selectively encourage senescent cells to die while sparing healthy cells.
Human trials generally favor a “hit-and-run” schedule involving short treatment pulses followed by weeks without treatment rather than continuous daily dosing. The goal is to reduce senescent-cell burden during the treatment period and then allow the body time to recover.
This cellular approach reflects the broader shift toward addressing the biology of aging and longevity rather than focusing exclusively on chronological age.
Current Evidence for Senolytic Therapy
Evidence surrounding senolytic therapy differs significantly between animal and human research.
Animal Data: Research is strong and relatively consistent. Senolytic therapies have demonstrated the ability to clear senescent cells and improve several measures associated with healthspan in mice.
Human Data: Evidence remains early. Small phase 1 and phase 2 trials involving diabetic kidney disease, pulmonary fibrosis, Alzheimer’s disease, and frailty are underway or have recently reported findings.
There is not yet a large, definitive human clinical trial demonstrating that senolytic therapy slows aging or extends lifespan.
For this reason, treatment should be presented as a carefully monitored, evidence-informed wellness strategy rather than a cure or guaranteed anti-aging treatment.
Core Senolytic Agents
Several compounds are currently being explored as potential components of a cellular-longevity program.
Dasatinib + Quercetin (D+Q)
Dasatinib and quercetin represent one of the most studied senolytic combinations, with early human clinical trials examining intermittent administration.
Published trials have used dasatinib 100 mg combined with quercetin 1250 mg for two consecutive days, with treatment intervals ranging from monthly to quarterly.
Dasatinib is a potent FDA-approved chemotherapy medication and requires particularly careful patient selection, medication review, monitoring, and medical supervision.
Fisetin
Fisetin has promising animal research behind it, although human efficacy has not yet been established.
Published research protocols have evaluated approximately 20 mg/kg/day for two consecutive days with treatment repeated at intervals ranging from monthly to quarterly.
Its comparatively cleaner safety profile has made fisetin an important compound of interest when evaluating lower-risk senolytic approaches.
Quercetin
Quercetin is frequently studied as a synergistic agent with dasatinib. Evidence supporting quercetin as a strong standalone senolytic is more limited.
Published protocols have commonly used approximately 1,000–1,500 mg on senolytic dosing days.
Spermidine
Spermidine is primarily considered an autophagy-promoting compound rather than a direct senolytic.
Typical supportive oral approaches discussed in longevity medicine range around 1–6 mg daily. Current evidence is largely observational, so spermidine is generally positioned as supportive rather than a proven longevity intervention.
Rapamycin & NAD+ as the Program Backbone
Senolytic therapy may be incorporated alongside other compounds being investigated for cellular aging and metabolic health.
Rapamycin (sirolimus) is an mTOR inhibitor that has become an important area of longevity research. Low-dose weekly approaches have been evaluated for tolerability, although rapamycin remains an off-label prescription therapy when used for longevity purposes.
Typical off-label approaches discussed in longevity medicine range from approximately 2–6 mg orally once weekly, often beginning around 1–3 mg and adjusting according to laboratory results and tolerance.
NAD+ serves as a cellular energy and repair cofactor and is another component frequently incorporated into longevity programs. Injectable and IV NAD+ protocols may be used as supportive interventions, although human outcome data regarding longevity remain limited.
Those interested in the role of NAD+ in metabolic and cellular support can also learn more about NAD+ for energy, metabolism, and longevity.
Neither rapamycin nor NAD+ has been proven to extend human lifespan, and treatment remains prescriber-directed.
Candidate Selection
Patient selection is an essential part of any investigational cellular-longevity program.
Reasonable candidates may include medically stable adults, generally age 40 or older, who have realistic expectations, understand the experimental nature of treatment, are willing to undergo appropriate monitoring, and provide informed consent.
Many potential candidates may already participate in broader wellness, hormone, or metabolic programs.
Certain patients require exclusion or specialist evaluation before treatment.
Dasatinib-specific concerns may include:
- Heart-rhythm history or long-QT concerns
- Blood-thinner use
- Active bleeding or recent surgery
- Significant heart, lung, liver, or kidney disease
- Low blood counts
- Uncontrolled diabetes
- Pregnancy or breastfeeding
Rapamycin-related concerns may include:
- Active infection
- Immunosuppression
- Poorly controlled lipid levels
- Poorly controlled blood sugar
- Pregnancy
- Planned surgery or wound-healing concerns
Patients taking complex medication regimens also require comprehensive interaction screening before treatment.
Intake & Baseline Workup
A structured baseline assessment establishes important safety benchmarks before treatment begins.
The initial evaluation should include:
- Complete medical history
- Full medication and supplement list
- Discussion of patient goals and expectations
- Complete blood count (CBC)
- Comprehensive metabolic panel
- Kidney and liver function
- Potassium and magnesium
- Fasting glucose and HbA1c
- Lipid panel
- An inflammatory marker such as hs-CRP
- IL-6 when available
Dasatinib candidates may also require a baseline ECG along with correction of low potassium or magnesium before treatment.
Optional aging biomarkers may include epigenetic biological-age testing. DunedinPACE is designed to evaluate pace of aging, while GrimAge and PhenoAge are also used in this area.
These biomarkers should be presented as research-grade measurements rather than diagnostic tests.
Because laboratory evaluation plays such an important role in treatment selection and follow-up, providers may also consider the broader importance of comprehensive blood testing when establishing patient baselines and monitoring changes over time.
Example Dosing Regimens
Published human research provides reference points for provider education, but these examples should not be interpreted as standing prescriptions.
Fisetin: Published research has evaluated 20 mg/kg orally on two consecutive days, repeated every one to three months.
Dasatinib + Quercetin: Research protocols have used dasatinib 100 mg plus quercetin 1250 mg on two consecutive days, repeated monthly to quarterly. Full cardiac and bleeding screening and appropriate electrolyte evaluation are particularly important.
Rapamycin: Off-label longevity approaches commonly discussed range from approximately 2–6 mg once weekly, often beginning at 1–3 mg and adjusting according to laboratory results and tolerance.
Spermidine: Approximately 1–6 mg orally each day has been discussed as a supportive autophagy-promoting approach.
NAD+: Injectable or IV administration may be incorporated according to established medically supervised protocols as a supportive intervention.
The underlying principle is intermittent dosing, conservative initiation, and reassessment after each cycle. Final treatment decisions belong to the prescribing provider and should be individualized to each patient.
Safety, Side Effects & Interactions
Among the compounds discussed, dasatinib requires the greatest degree of caution.
QT-Prolongation Risk: Baseline ECG evaluation and correction of potassium or magnesium abnormalities may be required. Other medications associated with QT prolongation should also be carefully reviewed.
Bleeding and Blood Counts: Dasatinib can increase bleeding concerns and affect blood counts. Particular caution is required when patients take anticoagulants or have existing hematologic abnormalities.
Pleural effusion with edema has also been reported as a serious adverse event in intermittent-dosing research.
CYP3A4 Interactions: Dasatinib can interact with CYP3A4 medications and grapefruit. It may also contribute to mild reductions in blood glucose among patients with diabetes.
Other potential adverse effects include rash, gastrointestinal symptoms, and bruising.
Quercetin is generally well tolerated but requires screening for interactions involving medications such as cyclosporine, digoxin, and fluoroquinolones.
Fisetin has also generally been well tolerated in available research, although absorption remains an important formulation consideration.
Spermidine currently has relatively few recognized interactions and is generally considered lower risk.
Rapamycin can affect immune function and may contribute to mouth sores and changes in lipid or glucose levels. It should be used cautiously around infections and surgical procedures.
Drug Interaction Alert: CYP3A4
Dasatinib and quercetin are both associated with CYP3A4 pathways.
Concurrent use with certain medications can potentially alter drug blood levels and increase the possibility of clinically significant adverse effects.
Medication classes requiring particular attention include:
- Statins
- Blood thinners such as warfarin, apixaban, and rivaroxaban
- Calcium channel blockers
- Immunosuppressants
- Antifungals such as ketoconazole and itraconazole
- Antibiotics such as clarithromycin and erythromycin
Complete medication reconciliation is required before dasatinib or high-dose quercetin is considered.
Monitoring & Adverse-Event Handling
Patients should be evaluated following their first treatment cycle, with relevant laboratory testing repeated according to the prescribed monitoring schedule.
Closer monitoring may be necessary for patients receiving dasatinib or rapamycin.
When biological-age markers are incorporated into the program, repeat testing may be considered at approximately six to twelve months.
Every clinical program should also establish a clear escalation pathway defining who patients should contact, when treatment should stop, and when urgent or emergency evaluation is necessary.
Warning signs may include:
- Chest pain
- Shortness of breath
- Abnormal or unexplained bleeding
- Significant swelling or edema
- Symptoms suggesting infection
Serious prescription-drug adverse events should be documented appropriately and reported to FDA MedWatch when applicable.
Pharmacy Compounding & Dispensing
Pharmacy involvement is an important component of a structured cellular-longevity program.
The objective of in-house compounding is to provide greater control over quality, patient-specific strength, formulation, documentation, and appropriate dispensing when legally permissible.
Potential components may include rapamycin, injectable or IV NAD+, fisetin, quercetin, spermidine, and patient-specific dasatinib plus quercetin preparations where permitted.
Compounding an FDA-approved medication under Section 503A requires an appropriate patient-specific basis, such as a custom strength, dosage form, or combination that is not commercially available, or another documented clinical or sourcing reason consistent with applicable requirements.
It should not simply be used to create a less expensive copy of a commercially marketed medication.
Supplement-origin substances such as fisetin, quercetin, and spermidine also require appropriate review regarding whether and how they may be compounded under applicable regulations.
API sourcing should involve reputable, documented suppliers with certificates of analysis.
Non-sterile preparations should follow applicable USP <795> requirements, while sterile preparations such as injectable or IV NAD+ must follow applicable USP <797> standards.
Quality, Labeling & Records
Quality assurance extends beyond the formulation itself.
Pharmacy documentation should include master formulation records, lot tracking, beyond-use dating, appropriate quality-control documentation, and certificates of analysis or stability information when applicable.
Clear patient labeling and dosing instructions are also critical.
Patient counseling and understandable dosing instructions are important safety measures, particularly when treatment involves intermittent schedules that differ substantially from ordinary daily medication use.
Providers and pharmacy teams should work together to ensure patients understand exactly when and how prescribed therapies are intended to be used.
Building a Controlled Cellular-Longevity Program
A structured program can progress through several stages rather than moving immediately into broad clinical use.
Foundation: Medical leadership reviews and approves protocols, informed-consent materials are developed, compounding requirements are confirmed, and appropriate sourcing and formulations are established.
Quiet Pilot: A small number of informed, lower-risk patients may be treated under close supervision, beginning with lower-risk approaches such as fisetin while baseline and follow-up data are collected.
Controlled Launch: After early processes have been evaluated, treatment may expand to a broader wellness population with more intensive pathways requiring full screening and monitoring.
Signature Program: A mature cellular-longevity program may incorporate ongoing monitoring, repeat testing, and integration with other medically supervised wellness, metabolic, hormone, or peptide-based health strategies when clinically appropriate.
Throughout every stage, patient outcomes, quality assurance, adverse events, and clinical documentation should remain central to the program.
Responsible Patient Communication
Language surrounding senolytic and longevity medicine matters.
Terms such as “reverse aging,” “cure,” or guaranteed longevity outcomes should not be used to describe experimental therapies.
Instead, communication should accurately characterize these approaches as evidence-informed, investigational, and performed under medical supervision.
No patient should be given the impression that senolytic therapy, rapamycin, NAD+, fisetin, quercetin, spermidine, or other longevity interventions have been proven to extend human lifespan.
As research continues, recommendations may evolve alongside better human clinical evidence.
Important Safety Information
This protocol is investigational and requires physician supervision. Dasatinib and rapamycin are prescription medications with significant toxicity profiles. No senolytic is currently FDA-approved specifically to treat aging, frailty, or extend lifespan.
All prescribing decisions require individualized clinical judgment, appropriate patient screening, informed consent, medication reconciliation, and ongoing monitoring.
The information presented here is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment.
Patients should always consult a qualified healthcare provider before beginning any new treatment or cellular-longevity protocol.
American Medical Wellness & American Wellness Pharmacy remain committed to safety, quality, appropriate clinical oversight, and personalized patient care.